FASN and neoplasm: Recent studies showed that TVB-3166—an orally available, reversible, potent, and selective FASN inhibitor—decreases viability in multiple tumor cell lines from solid and hematopoietic tumor types and tumor growth of patient-derived non-small-cell lung cancer xenograft tumors [12].